I. Policy:
Cosentyx (secukinumab) vials

II. Purpose/Objective:
To provide a policy of coverage regarding Cosentyx (secukinumab) vials

III. Responsibility:
A. Medical Directors
B. Medical Management
C. Pharmacy Department

IV. Required Definitions
1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions
Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
b. provided for the diagnosis and the direct care and treatment of the Member's condition, illness disease or injury;
c. in accordance with current standards good medical treatment practiced by the general medical community;
d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment
Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:

(i) the service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.
(ii) the service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.
(iii) the service or benefit will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.
DESCRIPTION:
Cosentyx (secukinumab) is a human IgG1 monoclonal antibody (immunomodulator) indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee

GRANDFATHER PROVISION – Members already established on therapy are eligible for approval as long as there is medical record documentation that the safety and effectiveness of use for the prescribed indication is supported by Food and Drug Administration (FDA) approval or adequate medical and scientific evidence in the medical literature.

Cosentyx (secukinumab) vials will be considered medically necessary when all of the following criteria are met:

1. **Plaque Psoriasis:**
   - Prescription must be written by a dermatologist AND
   - Member must be 18 years of age or older AND
   - Medical record documentation of a diagnosis of moderate to severe plaque psoriasis characterized by ≥ 5% of body surface area involved or disease involving crucial body areas such as the hands, feet, face, or genitals. AND
   - Medical record documentation that Cosentyx is not being used concurrently with a TNF blocker or other biologic agent AND
   - A therapeutic failure on, intolerance to, or contraindication to topical corticosteroids AND at least two to three months of systemic therapy (including but not limited to methotrexate and/or cyclosporine) or phototherapy OR medical record documentation of a therapeutic failure on or intolerance to prior biologic therapy.

2. **Psoriatic Arthritis:**
   - Medical record documentation of a diagnosis of moderately to severely active psoriatic arthritis which must include the following:
     - Documentation of either active psoriatic lesions or a documented history of psoriasis AND
   - Prescription must be written by a rheumatologist or dermatologist AND
   - Member must be at least 18 years of age AND
   - Medical record documentation that Cosentyx is not being used concurrently with a TNF blocker or other biologic agent AND
   - **For peripheral disease:** Medical record documentation of an intolerance to, contraindication to, or therapeutic failure on methotrexate AND an adequate trial of at least two (2) formulary NSAIDs OR medical record documentation of a therapeutic failure on or intolerance to prior biologic therapy OR
   - **For axial disease:** Medical record documentation of an intolerance to, contraindication to, or therapeutic failure to an adequate trial of at least two (2) formulary NSAIDs OR medical record documentation of a therapeutic failure on or intolerance to prior biologic therapy

3. **Ankylosing Spondylitis:**
   - Medical record documentation of a diagnosis of ankylosing spondylitis AND
   - Prescription must be written by a rheumatologist AND
   - Member must be at least 18 years of age AND
   - Medical record documentation that Cosentyx is not being used concurrently with a TNF blocker or other biologic agent AND
   - A therapeutic failure on, contraindication to, or intolerance to an adequate trial of at least two (2) NSAIDs OR a therapeutic failure on or intolerance to prior biologic therapy AND
   - Medical record documentation that the medication is being dosed as 150 mg every 4 weeks with or without a loading dose of 150 mg at Weeks 0, 1, 2, 3, and 4.
**AUTHORIZATION DURATION:** Approval will be given for an initial duration of six (6) months. For continuation of coverage, medical record documentation of clinical improvement or lack of progression in the signs and symptoms of the treated indication on six (6) months of Cosentyx therapy is required.

After the initial six (6) month approval, subsequent approvals will be for a duration of one (1) year, requiring medical record documentation of continued or sustained improvement in signs and symptoms of the treated indication while on Cosentyx therapy.

**LINE OF BUSINESS:**
Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy.

This policy will be revised as necessary and reviewed no less than annually.

**Devised:** 7/21/15

**Revised:** 7/19/16 (updated indication, psoriatic arthritis, ankylosing spondylitis), 3/20/18 (duplicate therapy, formulary alternatives), 4/24/18 (per DHS, grandfather)

**Reviewed:** 5/16/17, 1/30/19, 1/10/20